GUIDESMPS ProtocolsTechnical Methods
Practical Guide

Organ-on-Chip Protocols

Complete Technical Methods for Microphysiological Systems

Written by J Radler | Patient Analog
Last updated: January 2025

What You'll Learn

← Back to Guides

🧬 WHY THIS MATTERS

Organ-on-chip (OoC) technology represents the future of drug testing, offering human-relevant data that animal models cannot provide. Proper protocol execution is critical—even minor variations can compromise barrier integrity, cell viability, and experimental reproducibility.

90%[1]
Drug candidates fail in clinical trials
$2.6B[2]
Average cost per approved drug
87%[3]
OoC predictive accuracy for DILI
28
Days typical chip culture duration

⚠ PREREQUISITES

Required Skills

  • Aseptic cell culture technique (BSL-2)
  • Primary cell or iPSC handling experience
  • Basic microscopy and imaging
  • Microfluidic system operation
  • TEER measurement proficiency

Background Knowledge

  • Cell biology fundamentals
  • Fluid dynamics basics (shear stress)
  • ECM protein functions
  • Barrier physiology concepts
  • PDMS material properties

Facility Requirements

  • Class II biosafety cabinet
  • CO2 incubator (37C, 5% CO2)
  • Inverted microscope with live imaging
  • Laminar flow hood for chip assembly
  • TEER measurement system

⏰ TIME ESTIMATES

Chip Preparation
2-4 hours
ECM Coating
12-24 hours
Cell Seeding
2-6 hours
Barrier Formation
5-7 days
Compound Exposure
24-72 hours
Full Experiment
14-28 days

🛠 EQUIPMENT & MATERIALS

Equipment Purpose Est. Cost Priority
Organ-Chip Platform (Emulate Zoe) Automated chip culture system $150,000-250,000 Essential
TEER Measurement System (EVOM2) Barrier integrity monitoring $5,000-8,000 Essential
Peristaltic Pump System Continuous media perfusion $2,000-15,000 Essential
Syringe Pump (Harvard Apparatus) Precise flow rate control $3,000-6,000 Important
Plasma Cleaner (Harrick PDC-32G) PDMS surface activation $8,000-15,000 Important
Inverted Microscope + Camera Live cell imaging $15,000-50,000 Essential
Bubble Trap System Air bubble removal $500-2,000 Essential
Temperature-Controlled Stage Maintain 37C during imaging $3,000-8,000 Optional

🧪 Reagents & Consumables

Reagent Supplier Cat. No. Storage Price
Collagen I (Rat Tail) Corning 354236 4C $280/100mg
Fibronectin (Human Plasma) Sigma-Aldrich F2006 -20C $450/1mg
Matrigel (GFR) Corning 354230 -20C $380/10mL
PDMS (Sylgard 184) Dow Corning 4019862 RT $150/1.1kg
Lucifer Yellow Sigma-Aldrich L0259 -20C (dark) $95/100mg
FITC-Dextran (4kDa) Sigma-Aldrich 46944 -20C (dark) $180/250mg
Chip Tubing (0.5mm ID) Tygon/Cole-Parmer Various RT $50-100/50ft

📝 STEP-BY-STEP PROTOCOL

Phase 1: Chip Preparation (Day -1)

1
Inspect Chips for Defects

Remove chips from packaging under sterile conditions. Inspect under microscope at 4x-10x magnification for cracks, debris, or membrane defects. Reject any chips with visible damage. Document lot numbers.

2
Plasma Treatment (If Required)

For custom PDMS chips: Place in plasma cleaner chamber. Treat at 18W for 60-90 seconds with room air or oxygen plasma. This converts hydrophobic PDMS surface to hydrophilic for improved ECM adhesion. Use within 30 minutes of treatment.

3
Prepare ECM Coating Solution

Thaw Collagen I on ice (never at room temperature). Dilute to 50-100 ug/mL in cold PBS or manufacturer-recommended diluent. For Matrigel: thaw overnight at 4C, dilute 1:30-1:50 in cold DMEM/F12. Keep all solutions on ice to prevent premature gelation.

4
Coat Chip Channels

Slowly inject ECM solution into each channel using a micropipette. Avoid introducing air bubbles. Fill completely until solution exits opposite port. Incubate overnight at 4C (Collagen) or 1-2 hours at 37C (Matrigel). Aspirate excess before cell seeding.

Phase 2: Cell Seeding (Day 0)

5
Prepare Cell Suspension

Harvest cells at 80-90% confluence using appropriate dissociation method. For primary cells: use gentle enzymatic dissociation (Accutase). Count cells using hemocytometer or automated counter. Resuspend at 1-5 x 10^6 cells/mL in complete growth medium. Keep on ice until seeding.

6
Seed Endothelial Channel (Bottom)

For dual-channel chips: Seed endothelial cells (HUVEC, iPSC-EC) first into vascular channel. Inject 20-50 uL slowly. Invert chip and incubate 2 hours at 37C to allow ceiling attachment. Right the chip and add medium to both ports.

7
Seed Epithelial Channel (Top)

After 24 hours, seed tissue-specific epithelial cells (hepatocytes, gut epithelia, lung epithelia) into top channel. Adjust density based on cell type: hepatocytes 2-3 x 10^6/mL, Caco-2 5 x 10^6/mL. Incubate static for 4-6 hours to allow attachment.

8
Verify Cell Attachment

Image all chips at 10x magnification 24 hours post-seeding. Document cell morphology, confluence estimate, and any areas of poor attachment. Exclude chips with less than 70% confluence or abnormal morphology from experiment.

Phase 3: Flow Initiation (Days 1-3)

9
Connect Tubing and Reservoirs

Pre-fill all tubing with degassed, pre-warmed medium to eliminate air bubbles. Connect inlet tubing to medium reservoirs and outlet to waste collection. Use bubble traps at chip inlets. Verify all connections are secure and leak-free.

10
Calculate Target Flow Rates

Calculate flow rate using: Q = (tau * h^2 * w) / (6 * mu), where tau = shear stress (dyn/cm^2), h = channel height, w = channel width, mu = medium viscosity. Typical targets: 30 uL/hr (vascular), 10 uL/hr (epithelial). Verify with manufacturer specifications.

11
Initiate Low Flow

Start at 10-20% of target flow rate. Monitor for 30 minutes for any leaks, air bubbles, or cell detachment. Gradually increase flow rate over 24-48 hours to allow cells to adapt to shear stress. Monitor cell morphology daily.

12
Reach Target Shear Stress

Increase to full flow rate by Day 3. Endothelial cells require 0.5-2 dyn/cm^2 for proper alignment and junction formation. Epithelial cells tolerate lower shear (0.01-0.1 dyn/cm^2). Verify pump function daily.

Phase 4: Barrier Development (Days 4-7)

13
Monitor TEER Daily

Measure transepithelial electrical resistance using chopstick electrodes or integrated sensors. Target values: Caco-2 gut chip 300-600 ohm*cm^2, brain endothelium 150-300 ohm*cm^2, lung epithelium 800-1500 ohm*cm^2. Document trends.

14
Assess Permeability (Optional)

Add Lucifer Yellow (100 uM) or FITC-Dextran to apical channel. Collect basal effluent samples at 1, 2, 4 hours. Measure fluorescence and calculate Papp. Intact barriers should show Papp less than 1 x 10^-6 cm/s for Lucifer Yellow.

15
Verify Confluence and Morphology

Image chips at Day 7. Endothelial cells should show cobblestone morphology with aligned orientation in flow direction. Epithelial cells should form tight confluent monolayer. Exclude chips that fail to reach target TEER or show gaps in coverage.

Phase 5: Compound Exposure (Days 7+)

16
Establish Baseline Measurements

Collect effluent samples 24 hours before compound exposure. Measure baseline albumin, LDH, cytokines, and any tissue-specific markers (urea for liver, surfactant for lung). Store samples at -80C. Record baseline TEER.

17
Prepare Compound Solutions

Dissolve compounds in appropriate vehicle (DMSO for lipophilic, PBS for hydrophilic). Final DMSO concentration should not exceed 0.1%. Prepare fresh medium with compound at multiple concentrations (e.g., 0.1, 1, 10, 100 uM). Include vehicle control.

18
Initiate Exposure

Switch to compound-containing medium in apical channel (for oral bioavailability) or vascular channel (for systemic exposure). Maintain consistent flow rates. Collect effluent samples at defined timepoints (2, 6, 24, 48, 72 hours).

19
Monitor Toxicity Endpoints

Measure TEER daily during exposure. Analyze effluent for: LDH release (cell death), albumin/urea (liver function), cytokines (inflammation). Perform live/dead imaging at study endpoint. Calculate IC50 values from dose-response curves.

💡 EXPERT TIPS

Bubble Prevention

Degas all media overnight in vacuum chamber. Pre-warm medium to 37C before use—cold medium releases dissolved gases when warmed. Always use inline bubble traps.

Cell Viability

Primary hepatocytes are especially sensitive to shear. Use gravity-driven flow or very low pump rates (5-10 uL/hr) for the first 48 hours until cells spread and form junctions.

TEER Interpretation

TEER values are highly variable between systems. Always include positive controls (intact barrier) and negative controls (no cells or compromised barrier) to validate your measurements.

Sample Collection

Collect effluent into pre-chilled tubes with protease inhibitors for protein analysis. Snap-freeze immediately at -80C. Repeated freeze-thaw cycles degrade many biomarkers.

🔧 TROUBLESHOOTING GUIDE

Problem Possible Causes Solutions
Air bubbles in channels Inadequate degassing; Temperature changes; Leaky connections Degas media 24h under vacuum. Use inline bubble traps. Pre-warm all media to 37C. Check all luer-lock connections.
Poor cell attachment Insufficient ECM coating; Wrong ECM protein; PDMS hydrophobic Increase ECM concentration to 100 ug/mL. Try different ECM (fibronectin for endothelium, collagen for epithelium). Plasma treat PDMS immediately before coating.
Low TEER values Incomplete confluence; Damaged tight junctions; Wrong cell density Increase seeding density. Extend culture time before flow. Add ROCKi (Y-27632) for first 24h. Reduce shear stress for epithelial cells.
Cell detachment during flow Excessive shear stress; Inadequate attachment time; Air bubble damage Reduce flow rate. Allow 24-48h static attachment before initiating flow. Ramp up flow gradually over 48h. Use pulseless syringe pumps.
Bacterial contamination Non-sterile tubing; Contaminated reservoirs; Poor aseptic technique Autoclave all tubing and connectors. Use 0.22um filters on media lines. Change reservoirs every 48-72h. Work in BSC for all manipulations.
Inconsistent flow rates Pump malfunction; Partial channel occlusion; Tubing kinks Calibrate pump regularly. Check tubing for kinks or compression. Flush channels to remove debris. Replace worn tubing segments.
High background LDH Cell stress during seeding; Shear damage; Suboptimal medium Use gentle dissociation methods. Optimize seeding density. Verify medium formulation. Allow 48h recovery before baseline measurement.
Membrane delamination Excessive pressure; Manufacturing defect; Over-aggressive aspiration Reduce flow rate. Never apply positive pressure directly to chip. Aspirate gently from ports. Contact manufacturer for replacement.
Variable drug response Non-specific binding to PDMS; Inconsistent cell maturation; Flow rate variations Pre-saturate chips with compound-containing medium. Standardize culture duration. Include internal positive controls. Measure actual compound concentrations in effluent.
Poor imaging quality PDMS autofluorescence; Thick chip substrate; Condensation Use long working distance objectives. Minimize PDMS thickness. Pre-warm microscope stage. Use chips with glass bottoms for high-resolution imaging.

📊 COMMERCIAL PLATFORM COMPARISON

Platform Chip Types Throughput Automation Best For
Emulate Liver, Gut, Lung, BBB, Kidney 12 chips/instrument High (Zoe platform) Pharma DILI/GI studies
TissUse Multi-organ (HUMIMIC) 4-16 chips/plate Medium PK/PD multi-organ
MIMETAS OrganoPlate (3-lane) 40-96 chips/plate High (gravity flow) High-throughput screening
CN Bio PhysioMimix (liver focus) 12 chips/plate Medium Liver metabolism/DILI
Hesperos Human-on-Chip (multi-organ) 4-8 organs/system Low-Medium Systemic toxicity

❓ FREQUENTLY ASKED QUESTIONS

Q: What is the minimum equipment needed to start organ-on-chip research?
A: At minimum, you need: (1) a commercial chip platform or custom PDMS chips, (2) a peristaltic or syringe pump system, (3) an inverted microscope, (4) a CO2 incubator, and (5) TEER measurement capability. Budget approximately $50,000-100,000 for a basic setup, or $200,000+ for a fully automated platform like Emulate Zoe.
Q: How long can organ-chips be maintained in culture?
A: Most organ-chip studies run 7-28 days, though some systems support cultures exceeding 30 days. Liver chips have been maintained for up to 4 weeks with stable albumin production. The limiting factors are usually bacterial contamination risk, pump maintenance, and gradual decline in cell function. Plan compound exposure windows within the first 2 weeks for optimal data quality.
Q: Can I use primary human cells or only cell lines?
A: Both work, but primary human cells or iPSC-derived cells provide more physiologically relevant results. Cell lines (Caco-2, HepG2) are easier to culture and more reproducible but may lack important transporters or metabolic enzymes. For regulatory submissions, primary human hepatocytes or iPSC-hepatocytes are strongly preferred due to better CYP450 expression and drug metabolism profiles.
Q: What shear stress should I use for my organ type?
A: Target physiological values: arterial endothelium 10-20 dyn/cm^2, venous 1-5 dyn/cm^2, intestinal epithelium 0.02-0.08 dyn/cm^2, hepatocytes 0.1-0.5 dyn/cm^2. Most organ-chips operate at lower shear than in vivo to balance cell viability with physiological relevance. Start low (0.1-0.5 dyn/cm^2) and increase based on cell morphology and barrier function.
Q: How do I prevent compound adsorption to PDMS?
A: PDMS absorbs lipophilic compounds significantly. Strategies include: (1) pre-saturating chips with compound-containing medium for 24h before experiments, (2) using glass or thermoplastic chips instead of PDMS, (3) measuring actual compound concentrations in effluent rather than assuming nominal concentrations, (4) coating PDMS with parylene or other barrier coatings, (5) including mass balance calculations in your analysis.
Q: What is the best ECM coating for different cell types?
A: Recommended coatings: Collagen I (50-100 ug/mL) for hepatocytes and gut epithelia; Fibronectin (25-50 ug/mL) for endothelial cells; Matrigel (1:30-1:50 dilution) for iPSC-derived cells and complex epithelia; Laminin for neural cells. Some protocols use combination coatings (e.g., collagen/fibronectin mix). Always follow manufacturer protocols for specific chip platforms.
Q: How many replicates do I need for statistical power?
A: For toxicity studies, minimum n=3 chips per condition is standard, though n=4-6 is preferred for regulatory submissions. Account for chip failure rates (typically 10-20%) by preparing extra chips. For dose-response curves, test at least 4-6 concentrations spanning 3-4 log units. Include vehicle controls and positive controls (known toxic compound) in every experiment.
Q: Can organ-chips be used for FDA submissions?
A: Yes! The FDA Modernization Act 2.0 (2022) explicitly allows organ-chips and other NAMs as alternatives to animal testing. Several companies have successfully submitted organ-chip data to FDA. The ISTAND pilot program provides a formal pathway for MPS qualification. Contact FDA early in development to discuss your specific context of use and validation requirements.
Q: What are the main differences between organ-chips and organoids?
A: Organ-chips feature controlled microfluidic flow, defined tissue interfaces, and real-time barrier monitoring via TEER. Organoids are 3D self-organizing structures with more complex architecture but lack controlled perfusion and defined vasculature. Organ-chips excel at barrier studies and PK modeling; organoids are better for developmental biology and patient-specific cancer models. The two technologies are increasingly being combined.
Q: How do I validate my organ-chip model?
A: Validation should include: (1) structural characterization (morphology, marker expression, ultrastructure), (2) functional validation (tissue-specific functions like CYP450 activity, transporter function), (3) reference compound testing (known toxic and non-toxic compounds), (4) comparison to clinical data where available. Document sensitivity, specificity, and predictive value. Follow IQ MPS consortium recommendations for standardized validation approaches.

🔗 RELATED CONTENT

TECHNOLOGY
Organ-on-Chip Systems
Complete guide to OoC platforms
SCIENCE
Liver Toxicity Testing
DILI prediction methods
GUIDE
Drug Testing Methods
Compound screening protocols
COMPANY
Emulate Inc.
Leading OoC platform provider
REGULATORY
FDA ISTAND Program
MPS qualification pathway
GUIDE
Getting Started: Organoids
Complementary 3D culture guide

🎯 NEXT STEPS

  1. Select Platform: Evaluate commercial options vs. custom fabrication based on your throughput needs and budget
  2. Define Context of Use: Determine specific application (DILI screening, barrier function, PK modeling) to guide protocol optimization
  3. Pilot Studies: Run 2-3 pilot experiments with reference compounds before committing to full-scale studies
  4. Validate: Establish SOPs and demonstrate reproducibility across multiple operators and chip lots
  5. Engage Regulators: Contact FDA ISTAND program early if planning regulatory submissions
RELATED
Organoid Guide →
NEXT
Drug Testing Methods →
← Back to All Guides

Implementation Pathway

PhaseActivitiesTimeline
PlanningDefine objectives, select platform1-2 months
SetupInstallation, training, protocols2-3 months
ValidationTesting, regulatory engagement6-12 months

Next Steps

🎯

MPS Technology

Platform deep dive

🎯

Personalized Medicine

Patient approaches

🎯

FDA ISTAND

Submission pathways

Frequently Asked Questions

What are the key steps in organ chip protocols?

Steps include chip preparation and coating with extracellular matrix, cell seeding at defined density, media perfusion at physiological flow rates, culture for days to weeks allowing maturation, drug or stimulus addition, biomarker sampling at timepoints, and endpoint analysis with imaging or omics.

How do you coat chips with extracellular matrix?

Common coatings include collagen I (most tissues), fibronectin (endothelium), laminin (epithelium), or Matrigel (organoids). Protein solutions are injected into channels, incubated 1-4 hours at 37C, then washed before cell seeding. Coating concentrations typically range 50-500 micrograms per ml.

What cell seeding density is optimal?

Density depends on cell type and chip design. Epithelial cells seed at 1-5 million per ml to form confluent barriers. Hepatocytes seed at 10-20 million per ml for dense tissue. Neurons seed sparsely at 0.5-2 million per ml allowing network formation. Optimization required for each system.

How do you establish proper flow rates?

Flow rates are calculated from shear stress values in native organs (arterial: 10-15 dynes per cm squared, venous: 1-5, capillary: 0.1-1). For specific chip geometries, computational fluid dynamics modeling determines flow rate achieving target shear. Typical rates range 10-1000 microliters per hour.

What media formulations work best?

Media choice depends on cell types. Hepatocytes need hepatocyte maintenance medium. Neurons require neural basal media. Co-cultures need compromise formulations or sequential media changes. Serum-free defined media preferred for reproducibility though serum sometimes improves culture longevity.

How long should chips equilibrate before experiments?

Equilibration allows cells to attach, form barriers, and stabilize gene expression. Epithelial barriers need 3-7 days. Hepatocyte CYP450 expression stabilizes after 7-14 days. Cardiac maturation requires 14-21 days. Monitor biomarkers to confirm stability before adding drugs.

What are QC checkpoints during protocols?

Check cell viability post-seeding (should exceed 90 percent), barrier formation (electrical resistance or permeability), functional markers (albumin for liver, troponin for heart), morphology (phase imaging), and contamination (microscopy). Failed QC indicates protocol troubleshooting needed.

How do you sample from microfluidic chips?

Sampling methods include collecting effluent from outlet ports, removing aliquots from media reservoirs, or using integrated biosensors for non-destructive monitoring. Volume constraints (channels hold only microliters) require sensitive assays or pooling across timepoints.

What documentation is required for regulatory protocols?

Documentation includes detailed SOPs with step-by-step instructions, reagent lot numbers and vendors, equipment calibration records, quality control data, deviation logs, analyst training records, and data analysis plans. Regulatory protocols need validation showing reproducibility across analysts and sites.

Where can I find published organ chip protocols?

Published protocols appear in Nature Protocols, Journal of Visualized Experiments (JoVE), manufacturer application notes, and supplementary materials from research papers. Repositories like protocols.io provide community protocols. NCATS Tissue Chip website shares standardized methods.

📚 References

  1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014;32(1):40-51. DOI
  2. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20-33. PubMed
  3. Ewart L, Apostolou A, Briggs SA, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine. 2022;2:154. DOI